Drug
Naltrexone For Injectable
Naltrexone For Injectable: highest development phase Post-Market, developed by Alkermes. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| Naltrexone for extended-release injectable suspension NCT02978417 | Post-Market | Opioid-Related Disorders |
Latest
No recent events.
Follow Naltrexone For Injectable on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.